- Home
- JSPR
as 11-15-2024 4:00pm EST
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 302.0M | IPO Year: | N/A |
| Target Price: | $74.86 | AVG Volume (30 days): | 279.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.00 - $31.01 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Jasper Therapeutics Inc. News
JSPR Breaking Stock News: Dive into JSPR Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate
GlobeNewswire
4 days ago
Jasper Therapeutics to Participate at Upcoming Investor Conferences
GuruFocus.com
9 days ago
Analysts Bullish on Jasper Therapeutics as Briquilimab Trials Show Promise
GlobeNewswire
11 days ago
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
25 days ago
Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
GlobeNewswire
a month ago
Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria
GlobeNewswire
a month ago
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
GlobeNewswire
2 months ago
Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma
Compare JSPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JSPR Jasper Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.